Lung Cancer Management最新文献

Addition of pulsed electric field ablation to SBRT for lung tumors: effect on health-related quality of life. 在肺肿瘤的SBRT治疗中加入脉冲电场消融：对健康相关生活质量的影响

IF 2.1

Lung Cancer Management Pub Date : 2026-12-01 Epub Date: 2026-03-05 DOI: 10.1080/17581966.2026.2635332

Jeremy P Harris, Christina Boyd, Mengying Shi, Michael Reilly, Aaron Simon, Steven N Seyedin, Wen-Pin Chen, Misako Nagasaka, Nadine Abi-Jaoudeh, Michael A Hoyt

{"title":"Addition of pulsed electric field ablation to SBRT for lung tumors: effect on health-related quality of life.","authors":"Jeremy P Harris, Christina Boyd, Mengying Shi, Michael Reilly, Aaron Simon, Steven N Seyedin, Wen-Pin Chen, Misako Nagasaka, Nadine Abi-Jaoudeh, Michael A Hoyt","doi":"10.1080/17581966.2026.2635332","DOIUrl":"10.1080/17581966.2026.2635332","url":null,"abstract":"Introduction: Treatment indications for oligometastatic/oligoprogressive lung tumors are growing. Safety and lack of detrimental effect on patients' quality of life are critical for novel local therapies.Methods: We tested that the additive effect of pulsed electric field (PEF) ablation with lower-dose stereotactic body radiation therapy (SBRT) on health-related quality of life (HRQoL) as a secondary endpoint in a prospective clinical trial. FACT-Lung Cancer Subscale (FACT-LCS) and FACT-General domain surveys were collected at screening, 3 months, and 12 months. Functional clinical data included forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and diffusing capacity of the lung for carbon monoxide (DLCO).Results: Six patients with eight tumors were enrolled. Baseline well-being domain scores were: Physical 25.9 (Std Dev 2.3), Social 21.0 (Std Dev 6.9), Emotional 17.3 (Std Dev 4.7), Functional 21.2 (Std Dev 5.8), and LCS 19.4 (Std Dev 5.3). There were no significant changes following combined modality treatment in HRQoL domain scores or pulmonary function metrics after treatment. Lower EWB and SWB were associated with worse FVC and FEV1.Conclusion: In this small pilot study, no clinically meaningful declines in pulmonary function or patient-reported quality of life were observed at 3 months following combination therapy.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"15 1","pages":"2635332"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12969734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147356984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China. 中国一线接受ALK TKIs治疗的ALK阳性晚期NSCLC患者脑转移管理成本

IF 0.7

Lung Cancer Management Pub Date : 2026-12-01 Epub Date: 2026-02-03 DOI: 10.1080/17581966.2026.2622902

Bingqi Hu, Jing Xue, Dingsiman Li, Jia Duan, Luan Luan, Hannah Le, Peng Dong, Nada Rifi, Fanfan Zhu, Hongchao Li

{"title":"Cost of managing brain metastases in ALK-positive advanced NSCLC patients receiving first-line ALK TKIs in China.","authors":"Bingqi Hu, Jing Xue, Dingsiman Li, Jia Duan, Luan Luan, Hannah Le, Peng Dong, Nada Rifi, Fanfan Zhu, Hongchao Li","doi":"10.1080/17581966.2026.2622902","DOIUrl":"10.1080/17581966.2026.2622902","url":null,"abstract":"Aim: To estimate brain metastases (BM) management costs in Chinese ALK+ advanced non-small-cell lung cancer (NSCLC) patients receiving first-line (1 L) ALK tyrosine kinase inhibitors (TKIs).Methods: A survey of 105 clinical experts across 23 Chinese regions evaluated healthcare resource utilization (HCRU). Total annual costs with TKIs were calculated by weighting the management costs of patients with and without BM using the cumulative incidence rate (CIR) of BM from ALK-TKI clinical trials.Results: First-year management cost averaged ¥24,974 per-patient without BM versus ¥89,859 per-patient with BM, saving ¥64,885. Subsequent years saved ¥33,231. Applying 12-month CIR of BM, the annual costs per-patient were ¥26,791 for 1 L lorlatinib versus ¥46,516 for crizotinib in the intention-to-treat (ITT) population. Subgroup analysis showed annual costs of ¥25,623 per-patient with lorlatinib in those without BM and ¥29,775 in those with BM. Alectinib's and brigatinib's costs were ¥31,073 and ¥32,760 respectively, using the 12-month CIR of BM. Lorlatinib's cost savings increased progressively over 1-4 years. Limited CIR beyond 12 months existed for brigatinib and ensartinib. Results from the Asian group's CIR aligned with global trials.Conclusion: Due to lower BM CIR, lorlatinib showed higher BM management cost savings compared to crizotinib and alectinib in Chinese 1 L patients.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"15 1","pages":"2622902"},"PeriodicalIF":0.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12885437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146114262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer. 替波替尼与卡马替尼作为MET外显子14突变非小细胞肺癌后续治疗的成本-效果分析

IF 2.1

Lung Cancer Management Pub Date : 2026-12-01 Epub Date: 2026-04-04 DOI: 10.1080/17581966.2026.2654888

Mengmeng Liu, Lu Zhong, Tong Liu

{"title":"Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.","authors":"Mengmeng Liu, Lu Zhong, Tong Liu","doi":"10.1080/17581966.2026.2654888","DOIUrl":"10.1080/17581966.2026.2654888","url":null,"abstract":"Background: This study evaluated the cost-effectiveness of Tepotinib versus Capmatinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with MET Exon 14 Skipping Mutations in China.Methods: An economic evaluation using a 3-state partitioned survival model assessed the cost-effectiveness of Tepotinib versus Capmatinib. The Kaplan-Meier (KM) curves for overall survival (OS) and progression-free survival (PFS) from two clinical trials were digitally extracted. The Exponential model with matching-adjusted indirect comparison (MAIC) was employed at the end of the trials to extrapolate the long-term survivals.Results: The estimated cost and utility of Tepotinib treatment were higher than those of Capmatinib treatment, respectively (95,392.54 USD vs. 51,003.63 USD; 2.11 QALYs vs 1.38 QALYs). The incremental cost-effectiveness ratio (ICER) of Capmatinib treatment vs. Tepotinib treatment was calculated at 60,977.28 USD/QALY.Conclusions: Tepotinib was not cost-effective compared to Capmatinib as the second-line treatment for advanced or metastatic NSCLC patients with MET exon 14 skipping mutations in China.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"15 1","pages":"2654888"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13051608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147619000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leveraging machine learning to predict de novo skin malignancy following lung transplantation. 利用机器学习预测肺移植后皮肤恶性肿瘤。

IF 0.7

Lung Cancer Management Pub Date : 2026-12-01 Epub Date: 2026-01-19 DOI: 10.1080/17581966.2026.2617115

Nasim Nosoudi, Amir Zadeh, Rayna Nichols, Cameron Kiani, Jaime E Ramirez-Vick

{"title":"Leveraging machine learning to predict de novo skin malignancy following lung transplantation.","authors":"Nasim Nosoudi, Amir Zadeh, Rayna Nichols, Cameron Kiani, Jaime E Ramirez-Vick","doi":"10.1080/17581966.2026.2617115","DOIUrl":"10.1080/17581966.2026.2617115","url":null,"abstract":"Aims: This study aimed to predict post-transplant malignancy risks at multiple levels among lung transplant recipients using machine learning (ML) and to identify key clinical and immunogenetic predictors.Materials and methods: A dataset of 30,917 lung transplant recipients with no prior cancer history was analyzed using pre-, peri-, and post-transplant variables. Multiple ML algorithms-gradient boosting, random forest, neural networks, and logistic regression-were applied to predict: (1) overall de novo malignancies (DNM), (2) skin versus non-skin cancers, and (3) skin cancer subtypes, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).Results: Gradient boosting achieved the highest AUC for overall malignancies (0.746) and skin versus non-skin cancers (0.642), while random forest performed best for BCC versus SCC classification (AUC = 0.726). Significant predictors included HLA-DR alleles (DR52, DR1, DR53), A locus mismatch, recipient ethnicity, BMI, serum albumin, CMV/EBV serostatus, and cardiac-related measures (LV remodeling, cardiac output, prior cardiac surgery). Additional subtype predictors included peak PRA Class I sensitization, insulin signaling, donor-derived transfusions, and waiting list duration.Conclusions: ML-driven predictive modeling enables personalized assessment of post-transplant malignancy risk, supporting early detection, targeted surveillance, and optimized long-term care for lung transplant recipients.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"15 1","pages":"2617115"},"PeriodicalIF":0.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12826725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145999236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

At-home subcutaneous atezolizumab for non-small cell lung cancer: a prospective, single-arm phase II feasibility study. 家用皮下atezolizumab治疗非小细胞肺癌：一项前瞻性单臂II期可行性研究

IF 2.1

Lung Cancer Management Pub Date : 2026-12-01 Epub Date: 2026-10-04 DOI: 10.1080/17581966.2026.2738583

Lily Yang, Sana Iman Mutalib, Elizabeth Qi, Andrew Zeng, Jacob Thomas, Robert Hsu, Peter Kuhn, Luciano Nocera, Jorge Nieva

{"title":"At-home subcutaneous atezolizumab for non-small cell lung cancer: a prospective, single-arm phase II feasibility study.","authors":"Lily Yang, Sana Iman Mutalib, Elizabeth Qi, Andrew Zeng, Jacob Thomas, Robert Hsu, Peter Kuhn, Luciano Nocera, Jorge Nieva","doi":"10.1080/17581966.2026.2738583","DOIUrl":"10.1080/17581966.2026.2738583","url":null,"abstract":"Purpose: Frequent in-clinic cancer treatment can be burdensome, particularly for older adults and patients with limited mobility. This study aimed to assess the safety, feasibility, and patient experience of at-home subcutaneous (SC) atezolizumab injection administration in patients with non-small cell lung cancer (NSCLC).Patients and methods: This feasibility study included five patients with NSCLC treated with atezolizumab SC injections (1,875 mg every 21 days). The first three treatment cycles were administered in clinic, followed by nurse-administered home treatment. Patients underwent routine laboratory testing, telehealth visits, and standard disease monitoring. Safety, injection timeliness, treatment compliance, and patient satisfaction were evaluated over a total of 70 treatment cycles.Results: Of 70 total SC injections, 65 (93%) were delivered on time. No delays were attributable to atezolizumab SC administration. Two of five patients (40%) experienced an adverse event. Home administration required a shorter measured administration duration than in-clinic treatment (42.3 vs. 86.7 minutes). Digital monitoring engagement was limited. Mean Likert scores showed high overall satisfaction with drug administration (3.3/4) and preference for subcutaneous over intravenous administration (3.2/4).Conclusion: At-home atezolizumab SC administration was feasible in this small feasibility study and was associated with high patient satisfaction and shorter measured administration time.Clinical trial registration: ClinicalTrials.gov identifier is NCT05340309.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"15 1","pages":"2738583"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13644602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149116296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential to improve early detection of lung cancer through expansion of focused and opportunistic screening approaches: a scoping review focusing on potential expansion of screening risk factors and adoption of artificial intelligence models. 通过扩大重点筛查和机会性筛查方法改善肺癌早期检测的潜力：一项范围审查，重点关注筛查风险因素的潜在扩大和人工智能模型的采用。

IF 2.1

Lung Cancer Management Pub Date : 2026-12-01 Epub Date: 2026-10-12 DOI: 10.1080/17581966.2026.2743569

Tony S K Mok, Christian Finley, Deniz Köksal, Molly S C Li, Elaine Shum, Jeffrey B Velotta, Pan-Chyr Yang

{"title":"Potential to improve early detection of lung cancer through expansion of focused and opportunistic screening approaches: a scoping review focusing on potential expansion of screening risk factors and adoption of artificial intelligence models.","authors":"Tony S K Mok, Christian Finley, Deniz Köksal, Molly S C Li, Elaine Shum, Jeffrey B Velotta, Pan-Chyr Yang","doi":"10.1080/17581966.2026.2743569","DOIUrl":"10.1080/17581966.2026.2743569","url":null,"abstract":"Background: Low-dose computerized tomography (LDCT) is the gold standard for lung cancer (LC) screening, but access is hindered by strict eligibility criteria and limited infrastructure in low/middle-income countries. A combination of approaches, including expanded screening eligibility criteria and artificial intelligence (AI), could improve detection of early LC in patients excluded by current screening criteria.Areas covered: A scoping review was conducted (PubMed, Cochrane library, congresses) to explore two potentially complementary approaches to enhance LC screening. The first identified LC risk factors and their potential inclusion in expanded screening criteria, allowing more people at risk to become eligible for screening; the second examined studies involving AI-augmented imaging (CXR or LDCT) to improve workflow, triage, and opportunistic nodule detection.Expert opinion/commentary: Several robustly evidenced risk factors for LC were identified that are not included in current screening programs; widening of eligibility criteria could be considered based on local risk profile but requires further research to demonstrate benefit. Opportunistic use of AI-tools to assess incidental chest images may identify patients with pulmonary nodules requiring further investigation but their role in population-level LC screening requires prospective validation in diverse healthcare systems.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"15 1","pages":"2743569"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13671426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149171131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre. 单中心序贯ALK-TKI治疗的alk阳性NSCLC患者的临床特征

IF 2.1

Lung Cancer Management Pub Date : 2026-12-01 Epub Date: 2026-07-27 DOI: 10.1080/17581966.2026.2707910

Kohei Fujita, Takuma Imakita, Naoki Fujimoto, Saiki Yoshimura, Shogo Toyama, Takanori Ito, Issei Oi, Osamu Kanai, Yuki Yamamoto, Kiminobu Tanizawa

{"title":"Clinical characteristics of ALK-positive NSCLC patients treated with sequential ALK-TKI therapies in a single-centre.","authors":"Kohei Fujita, Takuma Imakita, Naoki Fujimoto, Saiki Yoshimura, Shogo Toyama, Takanori Ito, Issei Oi, Osamu Kanai, Yuki Yamamoto, Kiminobu Tanizawa","doi":"10.1080/17581966.2026.2707910","DOIUrl":"10.1080/17581966.2026.2707910","url":null,"abstract":"Introduction: Although sequential treatment with ALK-TKIs for ALK-positive lung cancer is commonly practiced in clinical settings, there are few reports on the actual treatment choices, efficacy and safety.Methods: This retrospective study evaluated the treatment sequence, progression-free survival (PFS), overall survival (OS), and adverse events (AEs) for the patients who received two or more ALK-TKIs.Results: Eleven patients were included in the study. The median age was 59 years, and five patients (45.5%) were female. The number of ALK-TKIs administered was two in five patients, three in five patients, and four in one patient. The drugs used were Alectinib in 10 patients, Lorlatinib in eight, Brigatinib in six, Ceritinib in three, and Crizotinib in two. Six patients (54.5%) had a history of treatment with cytotoxic chemotherapy in addition to ALK-TKIs. The most common first-line drug was Alectinib, followed by Brigatinib and Crizotinib. The median PFS for each treatment line was 23 months for the first line, 17 months for the second, 14 months for the third, and 5 months for the fourth. The median OS from 1st ALK-TKI was 58 months. Discontinuation of ALK-TKI due to adverse events occurred in six of the total treatment cases, and five of these (83.3%) were attributed to Brigatinib.Conclusion: Sequential treatment with different types of ALK-TKIs demonstrated a certain degree of efficacy. However, the incidence of discontinuation due to adverse events was higher for Brigatinib than for other ALK-TKIs.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"15 1","pages":"2707910"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13432833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148593830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

IF 2.1

Lung Cancer Management Pub Date : 2026-12-01 Epub Date: 2026-04-16 DOI: 10.1080/17581966.2026.2654211

引用次数: 0

CyberKnife radical cure for early lung adenocarcinoma: a case was confirmed by postoperative pathology. 射波刀根治早期肺腺癌1例经术后病理证实。

IF 2.1

Lung Cancer Management Pub Date : 2026-12-01 Epub Date: 2026-02-17 DOI: 10.1080/17581966.2026.2625649

Tingting Wang, Jingjing Fan, Xiaoyan Lv, Cong Zhang, Xiaoming Su

引用次数: 0

Surgical management of concomitant lung cancer and cardiovascular diseases: a multidisciplinary perspective. 肺癌合并心血管疾病的外科治疗：多学科视角

IF 0.7

Lung Cancer Management Pub Date : 2026-12-01 Epub Date: 2026-04-07 DOI: 10.1080/17581966.2026.2654371

Ryu Kanzaki, Jiro Okami

{"title":"Surgical management of concomitant lung cancer and cardiovascular diseases: a multidisciplinary perspective.","authors":"Ryu Kanzaki, Jiro Okami","doi":"10.1080/17581966.2026.2654371","DOIUrl":"https://doi.org/10.1080/17581966.2026.2654371","url":null,"abstract":"Lung cancer and cardiovascular diseases (CVDs) frequently coexist due to shared risk factors such as aging, smoking, and chronic inflammation. The growing prevalence of elderly surgical candidates with concomitant lung cancer and CVDs presents unique diagnostic and therapeutic challenges. This review explores current strategies for managing such patients, emphasizing the importance of individualized, multidisciplinary treatment planning. Advances in minimally invasive pulmonary resection and parenchymal -sparing surgery-such as segmentectomy-have expanded surgical options, especially in frail patients. Simultaneously, improvements in cardiovascular therapies, including transcatheter aortic valve implantation (TAVI), thoracic endovascular aortic repair (TEVAR), and off-pump coronary artery bypass grafting (OPCAB), have enabled safer, staged approaches. Guideline-directed preoperative risk assessment from Japanese, American, and European societies underscores the need for tailored sequencing of cardiac and oncologic interventions. In general, a staged approach with initial cardiac stabilization followed by pulmonary resection is preferred. However, simultaneous surgery, especially OPCAB combined with pulmonary resection, may be feasible in carefully selected patients. Additionally, the cardiac toxicity of immune checkpoint inhibitors and EGFR-TKIs must be considered when planning neoadjuvant treatment. Integrating cardiovascular expertise into thoracic oncology is crucial to optimizing outcomes in this complex population.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"15 1","pages":"2654371"},"PeriodicalIF":0.7,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147634789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0